COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò; Thomas Chatzikonstantinou; Gian Matteo Rigolin; Giulia Quaresmini; Marina Motta; Candida Vitale; Jose Antonio Garcia-Marco; José Ángel Hernández-Rivas; Fatima Mirás; Mónica Baile; Juan Marquet; Carsten U. Niemann; Gianluigi Reda; Talha Munir; Eva Gimeno; Monia Marchetti; Francesca Maria Quaglia; Marzia Varettoni; Julio Delgado; Sunil Iyengar; Ann Janssens; Roberto Marasca; Angela Ferrari; Carolina Cuéllar-García; Gilad Itchaki; Martin Špaček; Lorenzo De Paoli; Luca Laurenti; Mark-David Levin; Enrico Lista; Francesca R. Mauro; Martin Šimkovič; Ellen Van Der Spek; Elisabeth Vandenberghe; Livio Trentin; Ewa Wasik-Szczepanek; Rosa Ruchlemer; Dominique Bron; Maria Rosaria De Paolis; Giovanni Del Poeta; Lucia Farina; Myriam Foglietta; Massimo Gentile; Marino Gentile; Yair Herishanu; Tobias Herold; Ozren Jaksic; Arnon P. Kater; Sabina Kersting; Lara Malerba; Lorella Orsucci; Viola Maria Popov; Paolo Sportoletti; Mohamed Yassin; Barbara Pocali; Gabor Barna; Annalisa Chiarenza; Gimena Dos Santos; Eugene Nikitin; Martin Andres; Maria Dimou; Michael Doubek; Alicia Enrico; Yervand Hakobyan; Olga Kalashnikova; Macarena Ortiz Pareja; Maria Papaioannou; Davide Rossi; Dario Rossi; Nimish Shah; Amit Shrestha; Oana Stanca; Niki Stavroyianni; Vladimir Strugov; Constantine Tam; Mihnea Zdrenghea; Marta Coscia; Kostas Stamatopoulos; Giuseppe Rossi; Alessandro Rambaldi; Emili’ Montserrat; Robin Foà; Robin Foa; Antonio Cuneo; Paolo Ghia

doi:10.1038/s41375-020-0959-x

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta, Candida Vitale, Jose Antonio Garcia-Marco, José Ángel Hernández-Rivas, Fatima Mirás, Mónica Baile, Juan Marquet, Carsten U. Niemann, Gianluigi Reda, Talha Munir, Eva Gimeno, Monia Marchetti, Francesca Maria Quaglia, Marzia Varettoni, Julio Delgado, Sunil IyengarAnn Janssens, Roberto Marasca, Angela Ferrari, Carolina Cuéllar-García, Gilad Itchaki, Martin Špaček, Lorenzo De Paoli, Luca Laurenti, Mark-David Levin, Enrico Lista, Francesca R. Mauro, Martin Šimkovič, Ellen Van Der Spek, Elisabeth Vandenberghe, Livio Trentin, Ewa Wasik-Szczepanek, Rosa Ruchlemer, Dominique Bron, Maria Rosaria De Paolis, Giovanni Del Poeta, Lucia Farina, Myriam Foglietta, Massimo Gentile, Marino Gentile, Yair Herishanu, Tobias Herold, Ozren Jaksic, Arnon P. Kater, Sabina Kersting, Lara Malerba, Lorella Orsucci, Viola Maria Popov, Paolo Sportoletti, Mohamed Yassin, Barbara Pocali, Gabor Barna, Annalisa Chiarenza, Gimena Dos Santos, Eugene Nikitin, Martin Andres, Maria Dimou, Michael Doubek, Alicia Enrico, Yervand Hakobyan, Olga Kalashnikova, Macarena Ortiz Pareja, Maria Papaioannou, Davide Rossi, Dario Rossi, Nimish Shah, Amit Shrestha, Oana Stanca, Niki Stavroyianni, Vladimir Strugov, Constantine Tam, Mihnea Zdrenghea, Marta Coscia, Kostas Stamatopoulos, Giuseppe Rossi, Alessandro Rambaldi, Emili’ Montserrat, Robin Foà, Robin Foa, Antonio Cuneo, Paolo Ghia

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Lingua originale	English
pagine (da-a)	2354-2363
Numero di pagine	10
Rivista	Leukemia
Volume	34
DOI	https://doi.org/10.1038/s41375-020-0959-x
Stato di pubblicazione	Pubblicato - 2020

Keywords

Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents
Betacoronavirus
COVID-19
Comorbidity
Coronavirus Infections
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Pandemics
Pneumonia, Viral
Prognosis
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Surveys and Questionnaires

Accesso al documento

10.1038/s41375-020-0959-x

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Scarfò, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernández-Rivas, J. Á., Mirás, F., Baile, M., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., ... Ghia, P. (2020). COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 34, 2354-2363. https://doi.org/10.1038/s41375-020-0959-x

@article{21d6d95825f141e8833c5e7501188c9d,

title = "COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus",

abstract = "Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.",

keywords = "Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Betacoronavirus, COVID-19, Comorbidity, Coronavirus Infections, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Pandemics, Pneumonia, Viral, Prognosis, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Surveys and Questionnaires, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Betacoronavirus, COVID-19, Comorbidity, Coronavirus Infections, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Pandemics, Pneumonia, Viral, Prognosis, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Surveys and Questionnaires",

author = "Lydia Scarf{\`o} and Thomas Chatzikonstantinou and Rigolin, {Gian Matteo} and Giulia Quaresmini and Marina Motta and Candida Vitale and Garcia-Marco, {Jose Antonio} and Hern{\'a}ndez-Rivas, {Jos{\'e} {\'A}ngel} and Fatima Mir{\'a}s and M{\'o}nica Baile and Juan Marquet and Niemann, {Carsten U.} and Gianluigi Reda and Talha Munir and Eva Gimeno and Monia Marchetti and Quaglia, {Francesca Maria} and Marzia Varettoni and Julio Delgado and Sunil Iyengar and Ann Janssens and Roberto Marasca and Angela Ferrari and Carolina Cu{\'e}llar-Garc{\'i}a and Gilad Itchaki and Martin {\v S}pa{\v c}ek and {De Paoli}, Lorenzo and Luca Laurenti and Mark-David Levin and Enrico Lista and Mauro, {Francesca R.} and Martin {\v S}imkovi{\v c} and {Van Der Spek}, Ellen and Elisabeth Vandenberghe and Livio Trentin and Ewa Wasik-Szczepanek and Rosa Ruchlemer and Dominique Bron and {De Paolis}, {Maria Rosaria} and {Del Poeta}, Giovanni and Lucia Farina and Myriam Foglietta and Massimo Gentile and Marino Gentile and Yair Herishanu and Tobias Herold and Ozren Jaksic and Kater, {Arnon P.} and Sabina Kersting and Lara Malerba and Lorella Orsucci and Popov, {Viola Maria} and Paolo Sportoletti and Mohamed Yassin and Barbara Pocali and Gabor Barna and Annalisa Chiarenza and {Dos Santos}, Gimena and Eugene Nikitin and Martin Andres and Maria Dimou and Michael Doubek and Alicia Enrico and Yervand Hakobyan and Olga Kalashnikova and {Ortiz Pareja}, Macarena and Maria Papaioannou and Davide Rossi and Dario Rossi and Nimish Shah and Amit Shrestha and Oana Stanca and Niki Stavroyianni and Vladimir Strugov and Constantine Tam and Mihnea Zdrenghea and Marta Coscia and Kostas Stamatopoulos and Giuseppe Rossi and Alessandro Rambaldi and Emili{\textquoteright} Montserrat and Robin Fo{\`a} and Robin Foa and Antonio Cuneo and Paolo Ghia",

year = "2020",

doi = "10.1038/s41375-020-0959-x",

language = "English",

volume = "34",

pages = "2354--2363",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

}

Scarfò, L, Chatzikonstantinou, T, Rigolin, GM, Quaresmini, G, Motta, M, Vitale, C, Garcia-Marco, JA, Hernández-Rivas, JÁ, Mirás, F, Baile, M, Marquet, J, Niemann, CU, Reda, G, Munir, T, Gimeno, E, Marchetti, M, Quaglia, FM, Varettoni, M, Delgado, J, Iyengar, S, Janssens, A, Marasca, R, Ferrari, A, Cuéllar-García, C, Itchaki, G, Špaček, M, De Paoli, L, Laurenti, L, Levin, M-D, Lista, E, Mauro, FR, Šimkovič, M, Van Der Spek, E, Vandenberghe, E, Trentin, L, Wasik-Szczepanek, E, Ruchlemer, R, Bron, D, De Paolis, MR, Del Poeta, G, Farina, L, Foglietta, M, Gentile, M, Gentile, M, Herishanu, Y, Herold, T, Jaksic, O, Kater, AP, Kersting, S, Malerba, L, Orsucci, L, Popov, VM, Sportoletti, P, Yassin, M, Pocali, B, Barna, G, Chiarenza, A, Dos Santos, G, Nikitin, E, Andres, M, Dimou, M, Doubek, M, Enrico, A, Hakobyan, Y, Kalashnikova, O, Ortiz Pareja, M, Papaioannou, M, Rossi, D, Rossi, D, Shah, N, Shrestha, A, Stanca, O, Stavroyianni, N, Strugov, V, Tam, C, Zdrenghea, M, Coscia, M, Stamatopoulos, K, Rossi, G, Rambaldi, A, Montserrat, E, Foà, R, Foa, R, Cuneo, A & Ghia, P 2020, 'COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus', Leukemia, vol. 34, pagg. 2354-2363. https://doi.org/10.1038/s41375-020-0959-x

TY - JOUR

T1 - COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

AU - Scarfò, Lydia

AU - Chatzikonstantinou, Thomas

AU - Rigolin, Gian Matteo

AU - Quaresmini, Giulia

AU - Motta, Marina

AU - Vitale, Candida

AU - Garcia-Marco, Jose Antonio

AU - Hernández-Rivas, José Ángel

AU - Mirás, Fatima

AU - Baile, Mónica

AU - Marquet, Juan

AU - Niemann, Carsten U.

AU - Reda, Gianluigi

AU - Munir, Talha

AU - Gimeno, Eva

AU - Marchetti, Monia

AU - Quaglia, Francesca Maria

AU - Varettoni, Marzia

AU - Delgado, Julio

AU - Iyengar, Sunil

AU - Janssens, Ann

AU - Marasca, Roberto

AU - Ferrari, Angela

AU - Cuéllar-García, Carolina

AU - Itchaki, Gilad

AU - Špaček, Martin

AU - De Paoli, Lorenzo

AU - Laurenti, Luca

AU - Levin, Mark-David

AU - Lista, Enrico

AU - Mauro, Francesca R.

AU - Šimkovič, Martin

AU - Van Der Spek, Ellen

AU - Vandenberghe, Elisabeth

AU - Trentin, Livio

AU - Wasik-Szczepanek, Ewa

AU - Ruchlemer, Rosa

AU - Bron, Dominique

AU - De Paolis, Maria Rosaria

AU - Del Poeta, Giovanni

AU - Farina, Lucia

AU - Foglietta, Myriam

AU - Gentile, Massimo

AU - Gentile, Marino

AU - Herishanu, Yair

AU - Herold, Tobias

AU - Jaksic, Ozren

AU - Kater, Arnon P.

AU - Kersting, Sabina

AU - Malerba, Lara

AU - Orsucci, Lorella

AU - Popov, Viola Maria

AU - Sportoletti, Paolo

AU - Yassin, Mohamed

AU - Pocali, Barbara

AU - Barna, Gabor

AU - Chiarenza, Annalisa

AU - Dos Santos, Gimena

AU - Nikitin, Eugene

AU - Andres, Martin

AU - Dimou, Maria

AU - Doubek, Michael

AU - Enrico, Alicia

AU - Hakobyan, Yervand

AU - Kalashnikova, Olga

AU - Ortiz Pareja, Macarena

AU - Papaioannou, Maria

AU - Rossi, Davide

AU - Rossi, Dario

AU - Shah, Nimish

AU - Shrestha, Amit

AU - Stanca, Oana

AU - Stavroyianni, Niki

AU - Strugov, Vladimir

AU - Tam, Constantine

AU - Zdrenghea, Mihnea

AU - Coscia, Marta

AU - Stamatopoulos, Kostas

AU - Rossi, Giuseppe

AU - Rambaldi, Alessandro

AU - Montserrat, Emili’

AU - Foà, Robin

AU - Foa, Robin

AU - Cuneo, Antonio

AU - Ghia, Paolo

PY - 2020

Y1 - 2020

N2 - Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

AB - Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Betacoronavirus

KW - COVID-19

KW - Comorbidity

KW - Coronavirus Infections

KW - Female

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Male

KW - Middle Aged

KW - Pandemics

KW - Pneumonia, Viral

KW - Prognosis

KW - Protein Kinase Inhibitors

KW - Pyrazoles

KW - Pyrimidines

KW - Retrospective Studies

KW - SARS-CoV-2

KW - Severity of Illness Index

KW - Surveys and Questionnaires

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents

KW - Betacoronavirus

KW - COVID-19

KW - Comorbidity

KW - Coronavirus Infections

KW - Female

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell

KW - Male

KW - Middle Aged

KW - Pandemics

KW - Pneumonia, Viral

KW - Prognosis

KW - Protein Kinase Inhibitors

KW - Pyrazoles

KW - Pyrimidines

KW - Retrospective Studies

KW - SARS-CoV-2

KW - Severity of Illness Index

KW - Surveys and Questionnaires

UR - http://hdl.handle.net/10807/184028

U2 - 10.1038/s41375-020-0959-x

DO - 10.1038/s41375-020-0959-x

M3 - Article

SN - 0887-6924

VL - 34

SP - 2354

EP - 2363

JO - Leukemia

JF - Leukemia

ER -

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo